Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Dec;48(12):2482-5.
doi: 10.1007/s00125-005-0029-y. Epub 2005 Nov 12.

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS)

H M Colhoun  1 , D J Betteridge, P N Durrington, G A Hitman, H A W Neil, S J Livingstone, M J Thomason, J H Fuller; CARDS Investigators
Affiliations
Randomized Controlled Trial

Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS)

H M Colhoun et al. Diabetologia. 2005 Dec.

Abstract

Aims/hypothesis: The aim of this study was to determine the pattern of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin on cardiovascular events in patients with type 2 diabetes and no prior history of cardiovascular disease (CVD).

Materials and methods: A post hoc analysis of data from the Collaborative Atorvastatin Diabetes Study (CARDS), a randomised, placebo-controlled trial of 2,838 patients with type 2 diabetes, was performed. Patients received atorvastatin (10 mg daily) or placebo and were evaluated for cardiovascular and other outcomes over a median follow-up period of 3.9 years. Cox proportional hazards modelling was carried out, and the hazard ratios calculated for various times after randomisation to treatment were investigated.

Results: A reduction in the primary endpoint of major CVD events was apparent and statistically significant as soon as 18 months after treatment initiation. The effect of atorvastatin on CHD events was apparent by 6 months, and at 1 year was similar to the 37% relative risk reduction observed at trial closure.

Conclusions/interpretation: Atorvastatin alters the pathogenesis of CVD rapidly, such that the effect on cardiovascular events is apparent within months of initiation of therapy.

PubMed Disclaimer

References

    1. Lancet. 2004 Aug 21-27;364(9435):685-96 - PubMed
    1. JAMA. 2004 Mar 3;291(9):1071-80 - PubMed
    1. N Engl J Med. 2005 Jan 6;352(1):29-38 - PubMed
    1. N Engl J Med. 2005 Jan 6;352(1):20-8 - PubMed
    1. N Engl J Med. 2004 Apr 8;350(15):1495-504 - PubMed

Publication types

MeSH terms

LinkOut - more resources